PAH News Briefs

Rare Pancreatic Tumors Could Be a Comorbidity in Patients With PAH

Intraductal papillary mucinous neoplasms (IPMNs) could increasingly be seen as a comorbidity in patients with pulmonary arterial hypertension (PAH), especially as their life expectancy increases. This is according to a new case study published in the Chest journal and being presented at the Chest 2021 Annual Meeting. More research is needed to see whether the…

Case Report: Pulmonary Arterial Hypertension Due to Vitamin C Deficiency

Severe vitamin C deficiency is a rare cause of pulmonary arterial hypertension (PAH) that is easily treatable, according to a case study by Shrey Shah and colleagues published in Chest and being presented at the Chest 2021 Annual Meeting. It should, therefore, be considered in the appropriate clinical setting. The researchers presented the case of…

PAH May Be a Side Effect of Carfilzomib in Rare Cases

Two case reports highlight drug-induced pulmonary arterial hypertension (PAH) as a rare possible side effect of carfilzomib use in multiple myeloma patients. The reports were published in Pulmonary Circulation. Both patients presented with severe dyspnea and transthoracic echocardiograms (TTE) revealed elevated right ventricular systolic pressures (RVSP) after multiple treatments with carfilzomib. The first patient’s PAH…

Clinical trial

Application for New Imatinib Formulation for PAH Receives Clearance From FDA

Tenax Therapeutics received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a novel formulation of imatinib mesylate for the treatment of pulmonary arterial hypertension (PAH), according to a press release from the company. Tenax now plans to start a comparative pharmacokinetic study of the new formulation,…

pulmonary hypertension, diseased artery

Therapeutic Product Candidate Protects Rats Against PAH-Induced Bone Loss

RKER-012, a novel activin receptor type II ligand trap, protects against bone loss induced by pulmonary arterial hypertension (PAH) in a rat model of the disease. This is according to results from a preclinical study presented at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting. “We are excited to announce additional…

Pulmonary Arterial Hypertension Testing

Cardiac Ratio Could Be a New Prognostic Tool for Pediatric PAH

The ventricular-vascular coupling ratio (Ees/Ea) derived from pressure alone is a strong independent predictor of adverse outcomes in children with pulmonary arterial hypertension (PAH), according to a new study published in Open Heart. It could, therefore, be used as a powerful prognostic tool. Ventricular-vascular coupling is the ratio between the right ventricle’s contractile state (Ees)…

pulmonaty arterial hypertension etiology

No Change in Pulmonary Vascular Resistance Seen With Tocilizumab

Treatment with tocilizumab, an interleukin-6 (IL-6) receptor (IL6R) antagonist, caused no change in pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) in an open-label phase 2 clinical trial. Results were published in the European Respiratory Journal. “In summary, treatment with tocilizumab is feasible in PAH but demonstrated no significant effects on hemodynamics…

DNA gel close-up

Genetic Variant Identified as a Cause of Childhood-Onset PAH

Researchers identified a new biallelic variant in the ATP13A3 gene that causes dose-dependent childhood-onset pulmonary arterial hypertension (PAH) associated with high morbidity and mortality. This finding has implications in terms of disease prognosis and treatment strategies. The authors of the study, published in the Journal of Medical Genetics, stated, “Taken together, these findings demonstrate the…

Double and Triple Oral Therapies Reduce Pulmonary Vascular Resistance in PAH

Researchers have discovered that, in patients with newly diagnosed pulmonary arterial hypertension (PAH), both initial double oral therapy and initial triple oral therapy successfully reduced pulmonary vascular resistance by the end of a 26-week observation period, according to a study published in the Journal of the American College of Cardiology. “Pulmonary arterial hypertension (PAH) is…

PAH Patient Education

PAH Patients at Higher Risk of Anxiety During COVID-19 Pandemic

A team of Polish researchers has discovered through study groups that patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) had an increased risk of developing anxiety during the coronavirus disease 2019 (COVID-19) pandemic, according to a study published in the Journal of Clinical Medicine.  During the pandemic, patients with chronic cardiac…

Next post in PAH News Briefs